title: [Extravasation of chemotherapeutic agents: prevention and therapy].
abstract: Based on the potential to cause local tissue injury drugs are classified as vesicant, irritant and non-irritant. The frequency of extravasation is considered to be between 0.6 % and 6 %. More frequently an inflammatory reaction is caused by thrombophlebitis or a local hypersensitivity reaction following chemotherapy administration rather than by an extravasation. A number of factors are known to increase the risk of extravasation. By the consideration of these risk factors preventive guidelines for the safe administration of chemotherapeutic agents have been published. Central venous devices significantly reduce the risk of extravasation. To date there are no generally approved treatment guidelines for the management of extravasations. Treatment is mostly empirical. Nevertheless some general measures are to be recommended: Firstly, aspiration of the extravasated fluids should be attempted. Furthermore local supportive care such as intermittent topical warming or cooling is at least palliative and to a certain degree reduces the extent of the injury. Beside these non pharmacological therapies the beneficial effects of Dimethylsulfoxid (DMSO) -- or Hyaluronidase-administration dependent on the type of paravasation have been proven. The use of sodium bicarbonate, sodium thiosulfate or corticosteroids is no longer recommended. In the case of extravasation rapid and correct management is crucial for the benefit of any treatment. Therefore, written guidelines for both the handling of cytotoxic agents and also the management of an extravasation should be present in all Departments where cytotoxic agents are administered. In addition to these guidelines an extravasation kit including all necessary materials and drugs to treat extravasations should be available.
authors.affiliation: Klinik für Innere Medizin IV, Hämatologie/Onkologie; Martin-Luther-Universität Halle/Wittenberg, Halle. Karin.jordan@medizin.uni-halle.de
authors.forename: K
authors.initials: K
authors.lastname: Jordan
authors.forename: W
authors.initials: W
authors.lastname: Grothe
authors.forename: H-J
authors.initials: HJ
authors.lastname: Schmoll
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002405:Catheterization, Central Venous; D003937:Diagnosis, Differential; D004121:Dimethyl Sulfoxide / Q000008:administration & dosage; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007049:Iatrogenic Disease; D010447:Peptide Hydrolases / Q000008:administration & dosage; D011929:Razoxane / Q000008:administration & dosage; D012307:Risk Factors; D013885:Thiosulfates / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D013885:Thiosulfates; D011929:Razoxane; D010447:Peptide Hydrolases; C021430:hylase; C017717:sodium thiosulfate; D004121:Dimethyl Sulfoxide